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Background: Reliable phenotypic antimicrobial susceptibility testing can be a challenge in clinical settings in
low- and middle-income countries. WGS is a promising approach to enhance current capabilities.
Aim: To study diversity and resistance determinants and to predict and compare resistance patterns from WGS
data of Acinetobacter baumannii with phenotypic results from classical microbiological testing at a tertiary care
hospital in Tanzania.
Methods and results: MLST using Pasteur/Oxford schemes yielded eight different STs from each scheme. Of the
eight, two STs were identified to be global clones 1 (n"4) and 2 (n"1) as per the Pasteur scheme. Resistance
testing using classical microbiology determined between 50% and 92.9% resistance across all drugs. Percentage
agreement between phenotypic and genotypic prediction of resistance ranged between 57.1% and 100%, with
coefficient of agreement (j) between 0.05 and 1. Seven isolates harboured mutations at significant loci (S81L in
gyrA and S84L in parC). A number of novel plasmids were detected, including pKCRI-309C-1 (219000 bp) carrying
10 resistance genes, pKCRI-43-1 (34935bp) carrying two resistance genes and pKCRI-49-1 (11681bp) and
pKCRI-28-1 (29606bp), each carrying three resistance genes. New ampC alleles detected included ampC-69,
ampC-70 and ampC-71. Global clone 1 and 2 isolates were found to harbour ISAba1 directly upstream of the
ampC gene. Finally, SNP-based phylogenetic analysis of the A. baumannii isolates revealed closely related iso-
lates in three clusters.
Conclusions: The validity of the use of WGS in the prediction of phenotypic resistance can be appreciated, but at
this stage is not sufficient for it to replace conventional antimicrobial susceptibility testing in our setting.
Introduction
The burden of antimicrobial resistance is drastically increasing glo-
bally.1 MDR Gram-negative bacterial pathogens especially pose
major health challenges worldwide.2 Acinetobacter baumannii is
an important nosocomial pathogen and has been reported to
cause serious health problems due to its resistance to multiple
antimicrobial agents.3 Its ability as a non-lactose-fermenter to
grow with low nutritional requirements enables the pathogen to
survive in a wide range of environments.4 Historically, A. baumannii
infections have mainly been associated with severely ill patients in
ICUs and surgical wards and in people exposed to medical appar-
atus such as ventilators and catheters.5–7 Today, A. baumannii is
found across hospital wards and associated with various diseases
and/or surgical sites such as respiratory tract, bloodstream, urinary
tract and wound infections.8,9 It is becoming a leading cause of
nosocomial infections worldwide, with high mortality and morbid-
ity rates.3 In many cases, the infections involve MDR strains of the
pathogen.10
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A. baumannii possesses several mechanisms to resist a wide
range of existing antibiotic classes.3,11 These include production of
enzymes that can hydrolyse b-lactams, the presence of efflux
pumps and modifications of the outer membrane.12 The pathogen
has great capability to acquire new resistance determinants,13
which notoriously increases the threat it poses to global health.
European and other medically advanced countries started
monitoring antimicrobial resistance about 20 years ago.14,15 The
majority of these countries have formulated strategies to combat
this life-threatening disaster.16 Regular data generation on infec-
tion patterns, aetiological agents and their susceptibility patterns
over time is a core aspect of these strategies.
In developing countries, data to monitor trends and susceptibil-
ity patterns of common aetiological agents are infrequently pro-
duced,17 despite these data being crucial for formulating control
strategies and treatment guidance.18 Challenges encountered in
resource-limited countries include, for example, low-capacity
diagnostic tools, which hamper efforts to analyse and combat
antimicrobial resistance,16,19 and low availability of reliable pheno-
typic drug susceptibility testing resources in clinical laboratories,
resulting in untraceable resistance patterns for disease-causing
agents.
High-throughput diagnostic tools such as WGS hold great
promise in medical diagnostics and have proven to be invaluable in
the control of antimicrobial resistance.20 The use of such high-
throughput technologies to study pathogens has brought a break-
through in surveillance and monitoring in medically advanced
countries. Unfortunately, such tools are rarely available in
resource-limited countries.
In this study, we present what WGS can offer in tackling anti-
microbial resistance by applying this technology in Tanzania
where, as in the rest of the world, antimicrobial resistance is a ser-
ious and fast-growing health concern. We used WGS to identify
resistance determinants and predict phenotypic resistance in A.
baumannii from patients who were admitted to Kilimanjaro
Christian Medical Centre (KCMC), a referral hospital in northern
Tanzania. The isolates were sequenced and analysed locally at the
sequencing facility in the hospital’s research centre, Kilimanjaro
Clinical Research Institute (KCRI).
Materials and methods
Study design, location and sample collection
This study was part of a larger study that collected 286 wound/pus swabs
from 263 inpatients admitted to the medical or surgical departments of the
hospital.18 The study was a descriptive analysis to characterize isolates
from clinical specimens using WGS. This study was conducted at KCMC, a
tertiary healthcare facility for the northern zone of Tanzania. The clinical
specimens were collected during 2013 to 2015 from patients who were
admitted to the medical and surgical departments of the hospital.
Informed consent was obtained for all participants. Patient hospital files
were used to obtain sociodemographic and clinical characteristics of the
study participants. Data were then recorded on designated case report
forms.
Laboratory methods and data analysis
Clinical samples were collected during routine clinical care and transported
to the Microbiology Unit of KCRI Biotechnology Laboratory for routine micro-
biological analysis as previously described.18 The isolates were stored at
#80C before extraction of genomic DNA using the MasterPureTM Complete
DNA and RNA Purification Kit (Cat. No. MC85200; Epicentre, Illumina). The
quality and quantity of genomic DNA were confirmed using a Qubit 2.0
fluorometer (Life Technologies). Library preparation (dual indexing) was
done using the Nextera XT DNA Preparation Kit (Illumina Inc., San Diego, CA,
USA). WGS of the library was completed on an Illumina MiSeq using the
2%250 bp paired-end protocol. Patient characteristics were double data-
entered in OpenClinica. Excel sheets were extracted and exported to STATA
13 (StataCorp LP, TX, USA) for analyses.
MLST, antimicrobial resistance genes and SNP analysis
The raw reads were de novo assembled using SPAdes 3.6.0. The assembled
sequences were analysed to identify MLST STs and antimicrobial resistance
genes using offline versions of the MLST (version 1.7)21 and ResFinder (ver-
sion 2.1)22 tools available online from the Centre for Genomic Epidemiology
(CGE) at the Technical University of Denmark (http://cge.cbs.dtu.dk/serv
ices/). Phylogenetic distances were computed using an offline version of
the CSI phylogeny pipeline23 available at CGE (https://cge.cbs.dtu.dk/serv
ices/CSIPhylogeny/). Phylogenetic trees were generated with PhyML (ver-
sion 3.1, bootstrap count 100).24 The reference genome used was AYE
(NC_010410.1). MLST and their allelic profiles are indicated in Table S5
(available as Supplementary data at JAC Online).
Determination of plasmids, resistance regions and ISs
A combined approach using BLAST and ISfinder25 search, contig alignment
(Mauve,26 ACT27), read mapping (SRST2,28 Bowtie229), in-silico PCR (https://
github.com/zwets/blast-galley), rapid annotation (Prokka)30 and manual
inspection (Tablet)31 was used to analyse ISs. Unicycler32 and Bandage33
were used in the extraction of plasmid sequences.
Detection of fluoroquinolone mutations in A. baumannii
DNA gyrase gene sequences (gyrA, gyrB, parC and parE) were extracted
from the A. baumannii assemblies using gene-cutter, part of blast-galley
(commit 0d87ef, https://github.com/zwets/blast-galley). Reference pro-
teins used for A. baumannii were GyrA (D0CBH9) and ParC (D0CB90).
Nucleotide sequences were obtained from Ensembl Genomes (https://
ensemblgenomes.org). Alignment of the protein sequences was done using
MAFFT (version 7.271).34
Prediction of phenotypic drug resistance pattern using
WGS
ResFinder was used to predict resistance based on phenotypes from origin-
al published studies of resistance-conferring genes.35 Prediction of fluoro-
quinolone resistance was done based on mutations in gyrA and parC, as
there were no genes for fluoroquinolone resistance detected by ResFinder.
Intrinsic genes were included if mobile genetic elements such as ISAba1
were found directly upstream of the genes. Predictions were made for anti-
microbials including amoxicillin/clavulanate, ampicillin, cefazolin, ceftazi-
dime, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, nalidixic
acid and trimethoprim/sulfamethoxazole. These antimicrobials are com-
monly used in our setting. Correlation between the phenotypically tested
antibiotic resistance and predicted antibiotic resistance was determined
using Cohen’s Kappa coefficient of agreement (j) in eight drugs. Two drugs
were dropped as they were used in combination.
Ethics
Ethics approval for the study was obtained from the National Institute for
Medical Research, with certificate number NIMR/HQ/R.8a/Vol.IX/2080, and
from Kilimanjaro Christian Medical University College, with certificate num-
ber 891.
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Results
Characteristics of the study participants
The age range of the patients involved in this study was 11 to
92 years. Thirteen out of 14 patients were admitted due to
wound infections. The causes of wounds included surgery,
burns, cuts, diabetes mellitus, cancer, chronic ulcers and
bedsores. The length of hospitalization, where known, was from
7 to 44 days, with most of the patients recovering from their
conditions. One patient died after 20 days of hospitalization.
We could not trace hospitalization length and outcome for
four patients. One patient prematurely left the hospital by
absconding treatment. See Table 1.
Antimicrobial resistance pattern using classical
microbiology
The isolates were tested by conventional microbiology using a
panel of 10 antimicrobial agents. The overall resistance levels
ranged between 50% and 92.9% across all drugs. The highest re-
sistance level was 92.9% for cefazolin and ceftriaxone, followed by
ampicillin (85.7%), ceftazidime (78.6%), chloramphenicol
(71.43%) and trimethoprim/sulfamethoxazole (71.4%), gentami-
cin (64.3%), amoxicillin/clavulanate and nalidixic acid (57.1%) and
ciprofloxacin (50%). See Table 2.
MLST STs, antimicrobial resistance genes and plasmids
MLST yielded eight different STs. The most prevalent ST (n"4) was
global clone 1 (Pasteur scheme ST1). One isolate was of
global clone 2 (Pasteur scheme ST2). These global clones 1 and 2
were identified as ST405 and ST848, respectively, in the Oxford
scheme. Other recurring STs as per Pasteur/Oxford schemes were:
ST499/345 (n"3), ST625/860 (n"2), followed by single isolates for
ST979/1848, ST374/1325, ST1232/1846 and ST1233/1847. The
STs ST1232/1846 and ST1233/1847 were novel in both schemes,
whereas ST979/1848 was novel in the Oxford scheme. More infor-
mation on the allelic profiles of the isolates is in Table S4.
Several antimicrobial resistance genes representing resistance
to different antimicrobial agent groups were identified, located
Table 1. Sociodemographic characteristics associated with 14 A. baumannii bacterial isolates from patients who were admitted to medical and surgi-
cal departments of KCMC hospital
ID Collection date
Age
(years) Ward Gender Disease
Source of
sample
Length of
hospitalization
(days)
Patient
outcome
033 31 July 2013 49 medical 1 male respiratory infection sputum NI NI
043 1 August 2013 45 SICU B female burst abdomen wound swab 20 death
049 3 August 2013 29 surgical female burn wound wound swab NI NI
164C 21 March 2014 92 surgical female bedsores wound swab NI NI
518B 30 May 2015 29 surgical female burn wound wound swab 32 absconded
116 12 February 2014 20 surgical female burn wound wound swab 9 recovery
432B 11 March 2015 11 SICU B female burn wound wound swab NI NI
186B 4 April 2014 63 surgical male chronic leg ulcer wound swab 44 recovery
123C 18 February 2014 71 surgical female cut wound wound swab 9 recovery
363B 4 December 2014 58 surgical female scalp tumour wound swab 20 recovery
309C 16 September 2014 21 surgical male cellulitis wound swab 22 recovery
028 30 July 2013 33 surgical male cancerous wound wound swab 34 recovery
423 4 March 2015 49 surgical male chronic ulcer wound swab 7 recovery
558 14 July 2015 76 surgical male DM wound wound swab 34 recovery
DM, diabetes mellitus; NI, no information; SICU, surgical ICU.
Table 2. Phenotypic antimicrobial resistance pattern of the 14 A.
baumannii isolates
ID AMC AMP CFZ CAZ CRO CHL CIP GEN NAL SXT
116 I R R R R R R R I R
123C R R R R R R S S I R
309C R R R R R R S R S R
043 R R R R R R R R R R
432B R R R I R R R R R R
049 R R R R R S S S R S
033 I R R S R R S S S S
363 R R R R R R R R R R
423 I R R R R R R R R R
518B S S R R R I I R S R
558 R R R R R R R R R R
028 R R R R R R R R R R
164C I R R S R S S S S S
186B S S S R S S S S R S
R (%) 57.1 85.7 92.9 78.6 92.9 71.43 50 64.3 57.1 71.4
S (%) 14.3 14.3 7.1 14.3 7.1 21.43 42.9 35.7 28.6 28.6
I (%) 28.6 0.0 0.0 7.1 0.0 7.14 7.1 0.0 14.3 0.0
AMC, amoxicillin/clavulanate; AMP, ampicillin; CFZ, cefazolin; CAZ,
ceftazidime; CRO, ceftriaxone; CHL, chloramphenicol; CIP, ciprofloxacin;
GEN, gentamicin; NAL, nalidixic acid; SXT, trimethoprim/sulfamethoxa-
zole; R, resistant; S, susceptible; I, intermediate.
Kumburu et al.
1486
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/74/6/1484/5370329 by R
oyal Library C
openhagen U
niversity user on 20 M
ay 2019
either chromosomally or on plasmids. Chromosomally located
genes included aacC1, aadA1, aphA1, catA1, sul1, tet(A), tet(B), strA
and strB, while blaOXA-23, mph(E), msr(E), tet39, floR, sul2 and aadB
were found on plasmids. b-Lactamase genes included class D
(OXA-type) genes that are intrinsic factors in A. baumannii, blaPER-7
and the cephalosporinase-encoding gene ampC.
The three isolates of ST499/ST345 (116, 123C, 309C) were
found to carry an 219 kb plasmid exhibiting 93% identity with
Table 3. STs, resistance genes, mobile genetic elements and plasmids
ID
STs (Pasteur/
Oxford)
Mobile genetic
elements Intrinsic genes
Chromosomal resistance
genes
Plasmids, size and associated drug resistance
genes
116 499/345 CR (IS91), Intg1 blaOXA-95, ampC-70
b,
ampC-181b
ND plasmid: putative plasmid pKCRI-309C-1
Size: 219 kb
genes: arr-3, strB, armA, blaPER-7, cmlA1, mph(E),
msr(E), strA, sul1, dfrA26
plasmid: pAC450
123C 499/345 CR (IS91), Intg1 blaOXA-95, ampC-70
b,
ampC-181b
ND plasmid: putative plasmid pKCRI-309C-1
Size: 219 kb
genes: arr-3, strB, armA, blaPER-7, cmlA1, mph(E),
msr(E), strA, sul1, dfrA26
plasmid: pAC450
309C 499/345 CR (IS91), Intg1 blaOXA-95, ampC-70
b,
ampC-181b
ND plasmid: putative plasmid pKCRI-309C-1
Size: 219 kb
genes: arr-3, strB, armA, blaPER-7, cmlA1, mph(E),
msr(E), strA, sul1 dfrA26
plasmid: pAC450
43 625/860 IS3 and IS6,
ISAba1
blaOXA-90, ampC-4 ND plasmid: pKCRI-43-1
size: 34 935 bp
genes: floR, sul2
plasmid: pRAY
genes: aadB
432B 625/860 IS3 and IS6,
ISAba1
blaOXA-90, ampC-71
b ND plasmid: pKCRI-432-1
size: 34 935 bp
genes: floR, sul2
plasmid: pRAY
genes: aadB
49 374/1325 ND blaOXA-180, ampC-56 ND plasmid: pKCRI-49-1
size: 11 681 bp
genes: mph(E), msr(E), tet39
33 979/1848a ND blaOXA-51, ampC-50 ND ND
363 1/405 ISAba1 blaOXA-69, ampC-4 aacC1, aadA1, aphA1,
catA1, sul1, tet(A)
ND
423 1/405 ISAba1 blaOXA-69, ampC-4 aacC1, aadA1, aphA1,
catA1, sul1, tet(A)
ND
518B 1/405 ISAba1 blaOXA-69, ampC-4 aacC1, aadA1, aphA1,
catA1, sul1, tet(A)
presence suggestive of novel plasmids, not carry-
ing known resistance genes
558 1/405 ISAba1, ISAba4 blaOXA-69, ampC-4 aacC1, aadA1, aphA1, catA,
sul1, tet(A)
plasmid: pAB14
genes: blaOXA-23
28 2/848 ISAba1 blaOXA-66, ampC-2 aacC1, aadA1, strB, strA,
sul1, tet(B)
plasmid: pKCRI-28-1
size: 29 606 bp
genes: mph(E), msr(E), tet39
164C 1232a/1846a ND blaOXA-64, ampC-68
b ND ND
186 1233a/1847a ND blaOXA-51, ampC-69
b sul2 presence suggestive of novel plasmids, not carry-
ing known resistance genes
ND, not detected.
Note: pKCRI"new plasmid described in this study.
aNew STs identified in this study.
bNew ampC ST.
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the pIOMTU433 plasmid (AP014650) and 94% with the pA297-3
plasmid (KU744946). The plasmid hosted the arr-3, strB, armA,
blaPER-7, cmlA1, mph(E), msr(E), strA, sul1 and dfrA26 resistance
genes. See Table 3. The plasmid appeared structurally identical
to the pIOMTU433 plasmid, with differences concentrated in two
regions, each flanked bilaterally by ISs. The first region was adja-
cent to the class 1 integron-integrase gene intI1. Where
pIOMTU433 contains the sul2 gene, this was replaced in pKCRI-
309C-1 by a smaller segment containing the dfrA26 resistance
gene. This segment is present identically on plasmid pAB04-1
(CP012007). The second difference was an20 kb insert contain-
ing, among other genes, the mercury resistance operon. This
transposon is present nearly identically (99.94%) on pA297-3, a
plasmid that shares much of its sequence with pIOMTU433, but
lacks the class 1 integron and its downstream gene cassette that
pIOMTU433 and our ST499 isolates carry.
It was not possible to assemble the pKCRI-309C-1 plasmid into
a single contig, due to the inability of short-read sequencing to
‘read through’ larger repeated sequences. We hope to perform a
detailed follow-up analysis when long-read sequencing becomes
available to our laboratory in the future. The plasmid has been sub-
mitted to GenBank as an assembly of six unplaced contigs (acces-
sion pending).
The mph(E), msr(E) and tet39 genes, encoding macrolide, linco-
samide, streptogramin B and tetracycline resistance in isolates 28
and 49, seemed to be located on the novel plasmids pKCRI-28-1
(LR026972; 29606bp) and pKCR-49-1 (LR026974; 11681bp), re-
spectively. The plasmids also harboured a higA/higB toxin–anti-
toxin gene pair. This gene combination has been described for
other plasmids isolated from a global clone 2 strain, where the
tet39 and mph(E)-msr(E) were found to be in mobile modules
flanked by pdif sites.36 As in that study, tet39 was found in both
plasmids to be in a 2001 bp region flanked by inverted pdif sequen-
ces. The mph(E)-msr(E) gene pair was found, together with a
predicted resolvase/recombinase product (similar to
WP_015060246), in 4219 and 4300 bp regions, respectively,
flanked by pdif sites. The novel plasmid carried by isolate 28 add-
itionally encoded a putative cmlA/floR chloramphenicol efflux sys-
tem, located directly upstream of an ISL3-family transposase
separating it from the tet39 element.
The floR and sul2 resistance genes in isolates 43 and 432B were
determined to be on a novel 34 935 bp plasmid, pKCRI-43-1
(LR026973). Both genes were flanked by transposases: the floR
gene by IS3 and IS6-family (IS1008) transposases; and the sul2
gene by ISAba1 upstream and by glmM followed by IS91 and IS6-
family transposases downstream. The aadB gene in isolates 43
and 432B was found to be located on a pRAY plasmid present in
both isolates; the plasmid and its variants are widely distributed
and the most common cause of gentamicin and tobramycin re-
sistance in Acinetobacter spp.37
The blaOXA-23 gene of isolate 558 was found to be located on
plasmid pAB14, directly downstream of ISAba4, suggesting the
presence of transposon Tn2007 and the possibility of elevated car-
bapenemase production.38
Various other plasmids were identified in the isolates; no resist-
ance genes were detected on these plasmids. See Table 3.
AbaR resistance regions
The comM gene that is a prevalent location for insertion of AbaR re-
sistance regions39 was found to be interrupted in the four ST1 iso-
lates (363, 423, 518B and 558) and in the ST2 (28) isolate. The
comM gene was found intact in all other isolates. In silico PCR also
detected the presence of the left-hand side of Tn6019 in the ST1
and ST2 isolates and the right-hand side in the ST1 isolates.
ISs
Several isolates were found to have ISs upstream of their chromo-
somal b-lactamase genes. The four ST1 isolates (363, 423, 518B
and 558) and isolate 28 (ST2) had ISAba1 directly upstream of the
ampC gene. In the other isolates, no IS was found directly up-
stream of the ampC gene. In the three ST499 isolates, a common
region (CR) (IS91) was found directly upstream of the blaPER-7 gene
in the pKCRI-309C-1 plasmid. As pointed out above, in isolate 558
the plasmidic blaOXA-23 gene was found directly downstream of
ISAba4, constituting Tn2007. Few ISs overall were found in isolates
164C, 49 and the four ST1 isolates, whereas numerous ISs were
found in the three ST499 isolates (10–15 ISs) and notably isolate
186 (26 ISs).
Detection of fluoroquinolone mutations in A. baumannii
Mutations in gyrase/topoisomerase genes may confer resistance
by inhibiting fluoroquinolone binding. Half (7/14) of the A. bauman-
nii isolates were found to have mutations in gyrA (S81L) and in
parC (S84L), all exhibiting resistance to ciprofloxacin and nalidixic
acid. Among the other seven isolates without the double mutation,
only one was found to be fluoroquinolone resistant. All other iso-
lates had no relevant mutations. See Table 4.
Table 4. Mutations in fluoroquinolone resistance-determining genes of
A. baumannii
ID ST gyrA parC Ciprofloxacin Nalidixic acid
116 499/345 T82S — resistant intermediate
123C 499/345 T82S — susceptible intermediate
309C 499/345 T82S — susceptible susceptible
43 625/860 S81L S84L resistant resistant
432B 625/860 S81L S84L resistant resistant
49 374/1325 — — susceptible susceptible
33 979/1848a — — susceptible susceptible
363 1/405 S81L S84L resistant resistant
423 1/405 S81L S84L resistant resistant
518 1/405 S81L S84L resistant resistant
558 1/405 S81L S84L resistant resistant
28 2/848 S81L S84L resistant resistant
164C 1232a/1846a — — susceptible susceptible
186 1233a/1847a — — susceptible resistant
—, no relevant substitutions.
Mutations detected in fluoroquinolone resistance-determining regions in
A. baumannii. Seven out of 14 A. baumannii isolates were found to pos-
sess the mutations S81L in gyrA and S84L in parC.
aNew STs identified in this study.
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Prediction of phenotypic drug resistance pattern using
WGS
Percentage agreement between phenotypic and genotypic predic-
tion of resistance was 57.1% for ampicillin, 64.3% for cefazolin and
ceftriaxone, 71.4% for ceftazidime and nalidixic acid, 85.7% for
chloramphenicol and amoxicillin/clavulanate and 92.9% for tri-
methoprim/sulfamethoxazole and gentamicin. Ciprofloxacin was
the only drug with resistance predicted at 100%. The eight drugs
for which j was computed were cefazolin, ceftazidime, ceftriax-
one, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid and
ampicillin. j ranged between 0.05 and 1, i.e. between slight and
perfect agreement. Tables S1, S2, S3 and S4 summarize the correl-
ation between phenotypic and WGS-predicted resistance as deter-
mined by Cohen’s j.
SNP phylogenetic tree
From the SNP phylogenetic tree, three clusters of Tanzanian iso-
lates were observed. Cluster I contained the three isolates with
ST499/345. All three were isolated in 2014 (14 February,
18 February and 16 September). All had the T82S mutation in gyrA
and no mutations in parC. Isolates from this cluster all possessed
the plasmids pKCRI-309C-1 (accession pending), containing mul-
tiple antibiotic resistance genes, and pAC450, on which no resist-
ance genes were found. Cluster II contained the two isolates with
ST625/860. The isolates were collected on the same ward (surgical
ICU B), but 2 years apart, on 1 August 2013 and 11 May 2015. Both
isolates had the fluoroquinolone mutations S81L in gyrA and S84L
in parC and were ciprofloxacin resistant and nalidixic acid resistant.
The isolates both contained the pRAY plasmid carrying aadB and
pKCRI-43-1 (LR026973) containing floR and sul2. Cluster III con-
tained the four ST1/405 isolates. See Figure 1. Isolation dates were
4 December 2014, 4 March 2015, 30 March 2015 and 14 July 2015.
They all had the fluoroquinolone mutations S81L in gyrA and S84L
in parC and were all found to be resistant to ciprofloxacin and nali-
dixic acid. One of the four isolates possessed plasmid pAB14 con-
taining the blaOXA-23 gene. The five isolates that were not part of
the above-mentioned clusters were located at independent posi-
tions in the tree. The ST374/1325 isolate clustered closely with an
Australian isolate of the same ST, while the ST2/848 isolate clus-
tered with an isolate of the same ST collected in 2003 on an
American hospital ship. The remaining three isolates, which were
of novel STs, were all located at phylogenetically larger distances
from other isolates. Raw sequence data of the 16 A. baumannii
from our study have been submitted to the European Nucleotide
Archive (https://www.ebi.ac.uk/ena) under study accession num-
ber PRJEB26612. Plasmid accession numbers are: pKCRI-28-1
(LR026972); pKCRI-43-1 (LR026973); pKCR-49-1 (LR026974); and
pKCRI-309C-1 (accession pending).
Discussion
The current study aimed to investigate the diversity and resistance
determinants of A. baumannii isolates collected at a tertiary hos-
pital in Tanzania and to compare predicted resistance patterns
from WGS data with phenotypic results from classical microbio-
logical testing. The majority of patients investigated in this study
were hospitalized with wound infections and had relatively long
hospital stays despite the fact that many recovered. Hospitalized
patients with open wounds and long hospital stays are among
those who are vulnerable to A. baumannii infections. The pathogen
can persist on patients’ body surfaces or in the environment for a
considerable number of days, as the infections are difficult to
treat.40 The pathogen has the ability to resist many antibiotics
leading to fewer treatment options and sometimes death.9 It was
noted from the study that some patients abscond hospitalization
before recovery. In low-resource settings, patients who cannot af-
ford hospital charges will sometimes withdraw from treatment to
avoid further costs. Occasionally such patients will return to the
hospital with worsened conditions. Aforesaid behaviour could
cause hospital-based infections to be disseminated to the com-
munity and vice versa, with severe consequences when these
patients carry drug-resistant strains, which could then easily
spread to other susceptible persons.
MLST is one of the gold standards for determination of epi-
demiological relatedness of organisms.41 In this study MLST was
performed, based on both Pasteur and Oxford schemes.
Considerable genetic variation among A. baumannii strains was
observed. The observed variation included STs that represent the
global clones 1 and 2 of A. baumannii, as well as novel STs first iden-
tified in this study. The observed global clones are of great concern
as they are disseminated worldwide and have been highly associ-
ated with MDR. They have notably been associated with carbape-
nem resistance and outbreaks in hospital settings.42 Among the
global clones, one isolate was confirmed to possess the blaOXA-23
gene located on plasmid pAB14, directly downstream from
ISAba4, suggesting the presence of transposon Tn2007 and the
possibility of elevated carbapenemase production.38 Plasmid-
mediated class D b-lactamase genes, particularly blaOXA-23, play a
large role in mediating resistance.43 These findings are in contrast
to a study conducted in Tanzania that identified predominantly
IMP-type (class B) carbapenemases in A. baumannii isolates.44
SNP-based phylogenetic analysis of the A. baumannii further
confirmed the diversity by revealing three major clusters contain-
ing clades of closely related isolates. This observation, particularly
in the light of the time separation between isolation events, sug-
gests existence of specific strains of A. baumannii at the KCMC hos-
pital. The origin of these clones is not known, but it seems likely
that they dwell in the hospital environment and cause infections
over an extended period of time. Previous studies have reported on
A. baumannii isolates from medical apparatus, water systems and
handwashing sinks in the hospital environment, including ICUs
and surgical wards.45,46 These isolates tend to be MDR and hence
can persist for a long time if the reservoir is not destroyed, serving
as a potential source for recurrent outbreaks.
Isolates in clusters I and II were found to possess plasmid-
mediated resistance genes. The majority of these genes were situ-
ated in novel plasmids (pKCRI-309C-1 for cluster I and pKCRI-43-1
for cluster II). Cluster III consisted of global clone 1, for which in
some isolates resistance genes were found in both plasmids and
chromosomes. The coexistence of chromosomally and plasmid-
encoded b-lactamases and other genes in global clone isolates
has been observed in other studies.47,48 The isolate belonging to
global clone 2 in this study was found to carry chromosomally
mediated genes, as well as mph(E), msr(E) and tet39 genes encod-
ing macrolide, lincosamide, streptogramin B and tetracycline re-
sistance on a novel plasmid pKCRI-28-1.
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ISs have been associated with antimicrobial resistance through
multiple mechanisms: disruption of coding regions, mobilization of
gene cassettes and up-regulation of gene expression by additional
promoters.49 Our findings show that all global clone 1 and 2 iso-
lates studied were resistant to ceftriaxone despite the absence of
the genes responsible for resistance. However, the isolates were
found to harbour ISAba1 directly upstream of the ampC gene. This
configuration has been demonstrated to elevate ampC expression
levels, conferring resistance to third-generation cephalosporins.50
Isolates in Cluster I were identified as belonging to ST499/345 as
per Pasteur/Oxford schemes. Recent reports from other parts of
the world, including Egypt in Africa,51,52 reported isolates with
these STs to be associated with carbapenem resistance. In the cur-
rent study, these isolates were not confirmed to have resistance to
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APRE01_ST37/NF_CzechRepublic_1993
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Figure 1. SNP phylogeny analysis of 31 A. baumannii genomes that were isolated in 10 countries: Tanzania (TZ; current study), USA, UK, China,
Malaysia, Togo, Australia, Czech Republic, Iraq and Germany. From the SNP phylogenetic tree, three clusters for Tanzanian isolates were observed.
Cluster I was composed of three isolates with ST499/345 as per Pasteur/Oxford schemes. All had the T82S mutation in gyrA and had no mutations in
parC. Isolates from this cluster possessed pIOMTU433-like plasmids, which contained several antibiotic resistance genes, and pAC450, which did not
carry any resistance genes. Cluster II was composed of two isolates with ST625/860 as per Pasteur/Oxford schemes. Both isolates were isolated in
the surgical ICU B ward. They both had fluoroquinolone mutations S81L and S84L in gyrA and parC, respectively, and were ciprofloxacin resistant and
nalidixic acid resistant. The isolates contained more than one plasmid with no resistance genes on them with the exception of two: pA297-1, which
carried aadB; and pKCRI-43-1, containing the genes floR and sul2. Cluster III was composed of four isolates with ST1/405 as per Pasteur/Oxford
schemes. They all had fluoroquinolone mutations S81L and S84L in gyrA and parC, respectively. They were all resistant to ciprofloxacin and nalidixic
acid. Three possessed a novel plasmid and one possessed plasmid pAB14 containing blaOXA-23.
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carbapenems; however, they were found to harbour the novel
ampC allele ampC-70, encoding the novel amino acid sequence
AmpC-181. These isolates were further confirmed to possess CR
(IS91) directly upstream of the blaPER-7 gene in the pKCRI-309C-1
plasmid. These findings corroborate the observed phenotypic re-
sistance to ceftazidime and other cephalosporins that have been
reported from other studies.53
Antibiotic resistance to commonly prescribed antibiotics was
found to be high, with alarming resistance rates to fluoroquino-
lones and third-generation cephalosporins. The high resistance
rates are of great concern when it comes to A. baumannii, which is
a notorious nosocomial pathogen. Overprescription of antibiotics,
over-the-counter availability, self-medication, premature treat-
ment cessation, counterfeit drugs, poor diagnostic facilities and
other factors prevalent in low-income settings contribute greatly
to antibiotic resistance. Empirical treatment in such settings
becomes compromised and treatment options are reduced.54–56
Prediction of phenotypes from WGS data could be a powerful
potential application of next-generation sequencing technology in
low-resource settings, although limited studies have demon-
strated this.57 Given that sequencing technology is scarcely
deployed, especially in resource-limited settings, it is almost im-
possible to assess its power. However, the process of predicting
phenotypes is complex and it is currently in limited use.35
In the current study, the percentage agreement between
phenotypic and genotypic prediction of resistance ranged between
57.1% and 100%, with j ranging between 0.05 and 1. Our predic-
tion did not rely on the presence or absence of resistance genes
alone, but considered several other aspects. In some cases, genes
conferring resistance to drugs such as ciprofloxacin, nalidixic acid
and cefazolin were not detected by ResFinder, yet phenotypic re-
sistance was observed. In this case, other resistance mechanisms,
such as mutations in DNA gyrase/topoisomerase IV genes, were
responsible for resistance phenotypes. In the prevailing report we
detected significant mutations at 81/84 in gyrA/parC in the A. bau-
mannii isolates. Mutations at residues 81 and 84 in gyrA and parC,
respectively, are most frequently observed among the strains with
nalidixic acid and ciprofloxacin resistance, respectively. Other stud-
ies have reported the existence of triple mutations (gyrA, gyrB and
parC) that also contribute to development of a high level of fluoro-
quinolone resistance in clinical isolates of A. baumannii.58
However, for convenient determination of such mutation trends,
especially for the fluoroquinolones, a larger sample number is cru-
cial in future studies.
WGS techniques have great promise in providing sufficient and
reliable data for surveillance and monitoring of antimicrobial re-
sistance. Despite the technology being robust, limited knowledge
of bioinformatics data analysis is one of the major challenges. In
resource-limited settings, cost challenges and a lack of sequencing
expertise widen the gap to its potential utilization. These study
findings support the implementation in disease-endemic regions
of high-throughput techniques, to replace or add value to existing
technology, and hence take a step ahead in medical diagnostics.
Conclusions
The validity of the use of WGS in prediction of phenotypic resist-
ance can be appreciated, but at this stage is not sufficient to re-
place conventional antimicrobial susceptibility testing in our
setting. Classical microbiology still complements the genotypically
predicted resistance, as it provides better resolution of what is hap-
pening between organisms and their environment, taking into
consideration that observed phenotypes are a result of interaction
between genotypes and the environment.
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